SCHEMBL6959424

SCHEMBL6959424

CCCOC(=O)NN=Cc1ccc(C(=O)Nc2ccc3c(c2)CCC(CC(=O)OCC)O3)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.39
ITGA2B P08514 2/20 0.39
CYP1A2 P05177 2/20 0.38
RAB9A P51151 6/20 0.36
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
MIF P14174 1/20 0.35
POLB P06746 4/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 4/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949562 0.96 CYP1A2 (0.42) ITGB3ITGA2BCYP1A2RAB9AKMT2A
SCHEMBL6959165 0.93 ITGB3 (0.41) ITGB3ITGA2BCYP1A2RAB9AKMT2A
SCHEMBL6959308 0.89 ITGB3 (0.49) ITGB3ITGA2BCYP1A2RAB9AKMT2A
Hydrochloric Acid SCHEMBL6953870 0.86 ITGB3 (0.44) ITGB3ITGA2BRAB9ASMN1; SMN2POLB
SCHEMBL6957431 0.84 ITGB3 (0.52) ITGB3ITGA2BCYP1A2RAB9AKMT2A
SCHEMBL6959422 0.83 ITGB3 (0.47) ITGB3ITGA2BRAB9AKMT2ASMN1; SMN2
SCHEMBL8545467 0.82 ITGB3 (0.59) ITGB3ITGA2BRAB9AKMT2ASMN1; SMN2
SCHEMBL6954015 0.82 ITGB3 (0.51) ITGB3ITGA2BCYP1A2RAB9AKMT2A
SCHEMBL7081251 0.79 ALDH1A1 (0.47) ITGB3ITGA2BKMT2ASMN1; SMN2MAPT
SCHEMBL6803277 0.79 ITGB3 (0.60) ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130342-A1 Glycoprotein llb/llla antagonists FISHER MATTHEW J (US) 2003-07-10 US disclosed
EP-0804431-B9 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2003-01-02 EP disclosed
US-6448269-B1 SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS ELI LILLY AND COMPANY 2002-09-10 US disclosed
EP-0804431-B1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2002-07-24 EP disclosed
US-6020362-A ANTICOAGULANTS ELI LILLY AND COMPANY (US) 2000-02-01 US disclosed
EP-0804431-A4 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 1998-04-29 EP disclosed
US-5731324-A Glycoprotein IIb/IIIa antagonists ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
EP-0804431-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-11-05 EP disclosed
WO-1996022288-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130342-A1 Glycoprotein llb/llla antagonists SELL, SELPLG, LY96 ITGB3 653/4885ITGA2B 294/4885CYP1A2 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.